safety of glp-1 receptor agonists Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review agonist efficacy and GLP-1 Safety Warnings: What to
Description
doi: 10.1124/PR.115.011395 2 DruckerDJ
A new study found that females using GLP-1 drugs had about a 30% lower risk of developing breast cancer
J Reconstr Microsurg
Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS
Pharm Rev
Semaglutide has a cumulative exposure of over 22 million patient-years." "We will continue to invest in a variety of disease states including diabetes, chronic kidney disease, obesity, CV disease, liver disease, and Alzheimers disease, as seen in our robust clinical development programs and outcome studies," the statement continued
